Vortrag
Treatment with proprotein convertase subtilisin/kexin type 9 antibodies (PCSK9-I) in patients at high cardiovascular risk in clinical routine – new data regarding Familial Hypercholesterolaemia (FH) genotype related safety and effectivity
Autor:in
Datum:
06.05.2019 ,
Zeit:
11:03
|
Thema: Innere Medizin integral